Children in the world's poorest countries to get free insulin

Novo NordiskNovo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo.

It is estimated that some 38,000 African children aged 0–14 have type 1 diabetes. Sick children are particularly vulnerable in poor countries. A child in sub-Saharan Africa diagnosed with type 1 diabetes has a life expectancy of less than one year. A child with the same condition in the developed world has the possibility to live a full life.

"The premature death of a child caused by lack of insulin is unacceptable, when a life-saving solution is available. We must work together across borders to keep these children from dying; this is why I welcome this new programme being launched by Novo Nordisk today," says Professor Jean Claude Mbanya, president-elect of the International Diabetes Federation (IDF).

The programme will be based on a hub-and-spoke concept (satellite centres around existing hospitals/clinics) aimed at building long-term solutions for improving availability, accessibility, affordability and quality of diabetes care for children with type 1 diabetes.

"As a diabetes care company we have an obligation to use our resources and expertise to help these children. This project will not only provide insulin free of charge to an extremely vulnerable group, it is also designed to build long-term solutions for insulin distribution and sustainable diabetes care for all people with diabetes in the world's poorest countries," says Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk A/S.

To this end, the project’s aim is to collaborate with as many local partners as possible, including governments and diabetes associations, regional chapters of the International Diabetes Federation (IDF) and key opinion leaders. Efforts to improve the healthcare infrastructure of participating countries will also help the programme to survive after the project period ends.

"The World Diabetes Foundation is committed to funding capacity building, awareness creation and development of sustainable infrastructure within existing structures to improve the care for children with diabetes in developing countries. We will work with Novo Nordisk and other relevant stakeholders to achieve this objective," says Anil Kapur, managing director for the World Diabetes Foundation (WDF).

Novo Nordisk announced the 'Changing the Future for Children with Diabetes' programme in connection with the 60th anniversary of the United Nations Universal Declaration of Human Rights.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...